Effect of a 12-month Pharmaceutical Care Program on Control of Severe Asthma
NCT ID: NCT01644357
Last Updated: 2023-09-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
40 participants
INTERVENTIONAL
2008-08-31
2014-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The objective of this study is evaluate the effect of pharmaceutical care on asthma control and quality of life (QoL) of patients with severe or refractory asthma compared with pharmacist dispensation only.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Controller Medications in the Management of Bronchial Asthma
NCT01055041
Pharmacodynamic/Pharmacokinetic Interactions Between Oral Roflumilast and Inhaled Formoterol
NCT00940329
An ADME Study of [14C]AZD4604 and the Absolute Bioavailability of AZD4604
NCT06157255
Effect of a Pharmaceutical Intervention on the Level of Control of the Asthmatic Patient
NCT01085474
A Study to Compare the Pharmacokinetics (PK) of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152A (Test) or HFA-134A (Reference) in Healthy Participants Aged 18 to 55 Inclusive
NCT06433908
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dispensing only
Non clinical pharmacists will dispense drugs to patients and usual care will be offered.
No interventions assigned to this group
Pharmaceutical care
Patients on experimental group will receive counseling and education on the asthma condition, medication and lifestyle issues. In all visits, the inhaler technique will be reviewed, adherence to treatment and drug related problems were checked. If necessary the patient will be referred to the respiratory specialist to change the medication or to prescribe dose adjustment. Pharmacists document their initial and monthly follow up encounters using a specified form.
Pharmaceutical care
Pharmacist intervention, focused on the optimization of drug therapy, identification and resolution of drug related problems, resulting in best asthma control and quality of life. Pharmacists document their initial and monthly follow up encounters using a specified form. An action plan for self management of these patients was prepared and discussed aiming at early identification and treatment of an exacerbation episode. Meetings will be held weekly with intervention team to discuss action plan and measure of outcomes of all problems identified.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pharmaceutical care
Pharmacist intervention, focused on the optimization of drug therapy, identification and resolution of drug related problems, resulting in best asthma control and quality of life. Pharmacists document their initial and monthly follow up encounters using a specified form. An action plan for self management of these patients was prepared and discussed aiming at early identification and treatment of an exacerbation episode. Meetings will be held weekly with intervention team to discuss action plan and measure of outcomes of all problems identified.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ≥ 18 years of age,
* using high dose of inhaled corticosteroids (≥ 800mcg of budesonide or equivalent)
* FEV1\<60%,
* regular visitor of the pharmacy and the physicians.
Exclusion Criteria
* living in other cities,
* could not participate in all visits of the study
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Conselho Nacional de Desenvolvimento Científico e Tecnológico
OTHER_GOV
Federal University of Bahia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pablo de Moura Santos
Pharmacist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pablo M Santos, Master
Role: PRINCIPAL_INVESTIGATOR
Federal University of Bahia
Álvaro A Cruz, Professor
Role: STUDY_DIRECTOR
Federal University of Bahia
Lúcia B Noblat, Professor
Role: STUDY_CHAIR
Federal University of Bahia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Program for Asthma Control (ProAR) of the Federal University of Bahia
Salvador, Estado de Bahia, Brazil
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ATENFAR-PROAR
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.